Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 12/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25560594 | 0.83 | KMO (0.36) | KMOALDH1A1MAPK1SMN1; SMN2NTRK1 | |
| SCHEMBL25552102 | 0.82 | HCAR2 (0.38) | KMOMEN1KMT2ATDP1ALDH1A1 | |
| SCHEMBL25551849 | 0.80 | KMO (0.44) | KMOMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL30156974 | 0.80 | KMO (0.44) | KMOMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL25560591 | 0.79 | PDK1 (0.36) | KMOALDH1A1MAPK1SMN1; SMN2NTRK1 | |
| SCHEMBL25552093 | 0.79 | BTK (0.38) | TDP1ALDH1A1SMN1; SMN2BTKHTT | |
| SCHEMBL30037575 | 0.79 | BTK (0.38) | TDP1ALDH1A1SMN1; SMN2BTKHTT | |
| SCHEMBL25210699 | 0.79 | KMO (0.55) | KMOL3MBTL1 | |
| SCHEMBL25232381 | 0.78 | KMO (0.57) | KMOMEN1KMT2ABTK | |
| SCHEMBL25234137 | 0.76 | KMO (0.46) | KMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159508-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2023-05-25 | — | — | US | disclosed |
| CN-115515940-A | Inhibitors of receptor interacting protein kinase I for the treatment of disease | 德州大学系统董事会 | 2022-12-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159508-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | RIPK1, RIPK2, RIPK4 | KMO 3071/4885MEN1 4212/4885KMT2A 3766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.